Alcista
$391.81
Precio del escenario
$289.580
+7.240 (+2.50%)Al cierre
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.
Cigna Group (CI) is a good buy right now due to its current price of $282.43, which is significantly below the average analyst price target of $346 to $370, indicating potential upside. The forward P/E ratio of 8.26 suggests the stock is undervalued compared to its earnings growth potential, with analysts projecting an annualized earnings growth of approximately 11%. However, the RSI is at 73.37, indicating it may be overbought in the short term, which could lead to price volatility. The main risk is the insider selling, which has increased by 4982.25%, suggesting some lack of confidence from insiders.
Evercore ISI
$290
2026-09-09
Evercore ISI
2026-09-09
Precio objetivo
$290
Jefferies
$307
2026-08-04
Jefferies
2026-08-04
Precio objetivo
$307
Raymond James
$320
2026-08-03
Raymond James
2026-08-03
Precio objetivo
$320
Deutsche Bank
$305
2026-07-31
Deutsche Bank
2026-07-31
Precio objetivo
$305
Baird
$362
2026-07-31
Baird
2026-07-31
Precio objetivo
$362
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Cigna Group to Release Q3 2026 Financial Results on November 5

Cigna Group to Release Q3 2026 Financial Results

Cigna Launches Personalized Health Support Model

Cigna Launches Personalized Health Support Model

Cigna Group Unveils New Strategy to Enhance Healthcare Personalization
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).
Cigna Group (CI) is a good buy right now due to its current price of $282.43, which is significantly below the average analyst price target of $346 to $370, indicating potential upside. The forward P/E ratio of 8.26 suggests the stock is undervalued compared to its earnings growth potential, with analysts projecting an annualized earnings growth of approximately 11%. However, the RSI is at 73.37, indicating it may be overbought in the short term, which could lead to price volatility. The main risk is the insider selling, which has increased by 4982.25%, suggesting some lack of confidence from insiders.
17 analysts cover CI: 13 rate it Buy, 4 Hold and 0 Sell. The average price target is 335.63.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.